Neurocrine Biosciences director proposes $43.9K sale

The notice separately lists 101,649,181 common shares outstanding; that is distinct from the 300 shares proposed for sale.

Available on EDGAR 10/30/2026 - 04:20 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Neurocrine Biosciences director George Morrow filed a notice of a proposed sale of 300 common shares, with an approximate sale date of October 30, 2026. The notice lists an aggregate market value of $43,914 and names Morgan Stanley Smith Barney LLC as the broker. It identifies the shares as acquired from the issuer through exercise of stock options for cash.

Key Figures

Common shares proposed for sale: 300 shares Aggregate market value: $43,914 Common shares outstanding: 101,649,181 shares

3 metrics

Common shares proposed for sale 300 shares Approximate sale date: October 30, 2026

Aggregate market value $43,914 For the proposed sale

Common shares outstanding 101,649,181 shares Listed in the notice

Key Terms

Rule 144, Aggregate market value, Exercise of Stock Options

3 terms

Rule 144 regulatory

"paragraph (e) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Aggregate market value financial

"Aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Exercise of Stock Options financial

"Exercise of Stock Options"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NBIX shares did George Morrow report for sale?

George Morrow, a Neurocrine Biosciences director, reported a proposed sale of 300 common shares. The approximate sale date is October 30, 2026, and the notice lists an aggregate market value of $43,914.

How were the NBIX shares in George Morrow's proposed sale acquired?

The notice identifies the 300 common shares as acquired from the issuer through exercise of stock options, with cash listed as the form of payment. Morgan Stanley Smith Barney LLC is named as the broker.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001068754
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	NEUROCRINE BIOSCIENCES, INC.
SEC File Number	000-22705
Address of Issuer	6027 Edgewood Bend Court San Diego CALIFORNIA 92130
Phone	8586177600
Name of Person for Whose Account the Securities are To Be Sold	GEORGE MORROW
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	300	43914.00	101649181	10/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/30/2026	Exercise of Stock Options	Issuer			300	10/30/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	10/30/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ George Morrow
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)